Giant cell arteritis. Epidemiology and treatment

Area of Science:

• Rheumatology
• Immunology
• Epidemiology

Background:

• Giant cell arteritis (GCA) is an increasingly recognized cause of morbidity and mortality in the elderly.
• The etiology and pathogenesis of GCA remain poorly understood, with potential environmental and genetic influences.
• Epidemiological studies indicate highest incidence in Northern European populations, suggesting genetic or environmental risk factors.

Purpose of the Study:

• To review the current understanding of Giant Cell Arteritis (GCA).
• To discuss the epidemiology, pathogenesis, and management of GCA.
• To evaluate the role of glucocorticosteroids and other anti-inflammatory drugs in GCA treatment.

Main Methods:

• Review of epidemiological data on GCA incidence across different populations.
• Analysis of current treatment guidelines and clinical studies for GCA.
• Evaluation of the efficacy and safety of glucocorticosteroids and NSAIDs in GCA management.

Main Results:

• GCA incidence is increasing and varies geographically, with higher rates in Northern Europe.
• Glucocorticosteroids, particularly prednisolone, are the mainstay of GCA treatment.
• Low maintenance doses of prednisolone (5-7.5 mg/day) are effective with relatively low adverse effects, and treatment duration averages 5 years.

Conclusions:

• Giant cell arteritis is a significant health concern in the elderly population.
• Glucocorticosteroids are effective for GCA, with careful dosage management minimizing side effects.
• Nonsteroidal anti-inflammatory drugs (NSAIDs) lack proven efficacy in preventing vascular complications of GCA and are not recommended.